Depression
Conditions
Interventions
Participants take 1-gram tryptophan (2 capsules) and identical placebo capsules
three times daily with meals (in total 3 x 2 = 6 capsules per day) for 14 days
each in a randomized, counterbalanced o
Sponsors
Rijksuniversiteit Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Age 18-65 years • At least one first-degree family member with MDD • Willingness to cooperate; to sign written informed consent
Exclusion criteria
Exclusion criteria: • Any current or past MDD or other mood disorder as determined by the SCID-NP • Any current anxiety disorder, psychotic disorder, substance use disorder, eating disorder, or somatoform disorder as determined by SCID-NP • Any contraindication for the use of tryptophan, i.e. pregnancy, diabetes, cancer or a history of cancer, a history of any scleroderma-like condition, evidence of achlorhydria, upper bowel malabsorption, or irritation of the urinary bladder • Current use of psychotropic medications including medications for psychiatric problems (e.g., antidepressants such as MAO inhibitors and fluoxetine) or migraines • Not speaking Dutch fluently
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is the level of quarrelsome behaviour measured using ecological momentary assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures include levels of agreeable, dominant, and submissive behaviours, as well as affect, cognitions, and perceptions. Finally, polymorphisms of genes thought to be related to MDD may be determined. | — |
Countries
Netherlands
Outcome results
None listed